Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TulmiSTAR-01
2025-521880-10-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Feb 2026
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of tulmimetostat and luxdegalutamide in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities and safety/tolerability and PSA50 at Month 6. Planned start Feb 2026; status: authorised.
02
Drugs
tulmimetostatluxdegalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2025-521880-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521880-10-00.